Technology Networks spoke to Professor Thomas Rademacher, co-founder, executive director and CEO at Gylden Pharma Limited, to ...

Scientists at La Trobe University have identified a possible defense for humans against the influenza virus H5N1—commonly ...

Helper T cells recognize antigenic peptides that are bound to the MHC class II molecules, whereas CD8 + cytotoxic T cells are bound to the MHC class I molecules. Therefore, small peptides that are ...

This research comes as dengue-carrying mosquitoes expand their territory into new regions, including Southern California.

Children who experience multiple cases of dengue virus develop an army of dengue-fighting T cells, according to a new study led by scientists at La Jolla Institute for Immunology (LJI).

In a breakthrough for influenza research, scientists have discovered immune cells that can recognize influenza (flu) viruses even as they mutate, raising hopes for a longer-lasting vaccine and a ...

Human T-lymphotropic ... cells. In addition, Dr. Marriott worked with collaborators at the CDC to develop reagents that can be used to determine the prevalence of HTLV-3 infection in humans and to ...

A phase II trial found that T-VEC improved tumor resectability ... effectiveness of a neoadjuvant oncolytic virus (OV) therapy in cutaneous basal cell carcinoma (BCC). The incidence of cutaneous ...

Clinical trials planned to begin patient enrollment during 2025 to evaluate Gylden’s T cell Priming (TcP) candidates against Dengue (Phase II) ...